Teacher Retirement System of Texas Sells 884 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Teacher Retirement System of Texas lessened its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 7.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,931 shares of the company’s stock after selling 884 shares during the period. Teacher Retirement System of Texas’ holdings in Janux Therapeutics were worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in JANX. GAMMA Investing LLC raised its stake in Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after acquiring an additional 1,574 shares during the period. Russell Investments Group Ltd. raised its stake in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics in the 4th quarter valued at $59,000. FNY Investment Advisers LLC raised its stake in Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after acquiring an additional 2,425 shares during the period. Finally, KBC Group NV bought a new stake in Janux Therapeutics in the 1st quarter valued at $66,000. Institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Raymond James Financial started coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 price target on the stock. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics has an average rating of “Buy” and an average price target of $91.89.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider directly owned 82,139 shares of the company’s stock, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.10% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $26.40 on Friday. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -19.41 and a beta of 2.86. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock’s fifty day moving average price is $24.62 and its two-hundred day moving average price is $31.44.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.